4142:TPE
Adimmune Corp
NT$16,80
arrow_upward
+0,60%(+0,100) 1D
13 ພ.ຈ., 13 ໂມງ 30 ນາທີ 11 ວິນາທີ GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
NT$16,85
High
NT$17,15
Low
NT$16,75
Mkt. cap
7,22 ຕື້
Avg. vol.
1,13 ລ້ານ
Volume
724,64 ພັນ
52-wk high
NT$22,50
52-wk low
NT$15,65
EPS
NT$-0,34
Shares outstanding
235,29 ລ້ານ
No. of employees
564
Open
NT$16,85
High
NT$17,15
Low
NT$16,75
Mkt. cap
7,22 ຕື້
Avg. vol.
1,13 ລ້ານ
Volume
724,64 ພັນ
52-wk high
NT$22,50
52-wk low
NT$15,65
EPS
NT$-0,34
Shares outstanding
235,29 ລ້ານ
No. of employees
564
News stories
From web sources and news partners
24/7 Wall St.
·
21 ນາທີກ່ອນ
He Thinks His $200,000 S&P 500 401(k) Spreads His AI Risk. Two Alphabet Share Classes Put $10,380 in One Company. A 20% Drop Could Cost Him $2,076
TradingView
·
4 ຊົ່ວໂມງກ່ອນ
SpaceX's S&P 500 bid gets new life as Elon Musk pitches Tesla merger
The Motley Fool
·
7 ຊົ່ວໂມງກ່ອນ
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
Traders Union
·
4 ຊົ່ວໂມງກ່ອນ
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadimmune.com.tw